BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9190963)

  • 1. Tumor lymphocytes in patients with advanced ovarian cancer: changes during in vitro culture and implications for immunotherapy.
    Han X; Papadopoulos AJ; Ruparelia V; Devaja O; Raju KS
    Gynecol Oncol; 1997 Jun; 65(3):391-8. PubMed ID: 9190963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors.
    Heo DS; Whiteside TL; Kanbour A; Herberman RB
    J Immunol; 1988 Jun; 140(11):4042-9. PubMed ID: 3286766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites.
    Ioannides CG; Platsoucas CD; Rashed S; Wharton JT; Edwards CL; Freedman RS
    Cancer Res; 1991 Aug; 51(16):4257-65. PubMed ID: 1868446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
    Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
    Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The comparison of biological characteristics between tumor-infiltrating lymphocytes and tumor-associated lymphocytes in ascites of epithelial ovarian carcinoma].
    Kang S; Shen K; Lang J
    Zhonghua Fu Chan Ke Za Zhi; 1998 Oct; 33(10):607-10. PubMed ID: 10806687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
    Strauss G; Gückel B; Wallwiener D; Moldenhauer G
    Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of immunocellular resistance to IL-2-activated lymphocytes within ovarian carcinoma cells.
    Papadopoulos AJ; Han X; Matossian-Rogers A; Raju KS
    Gynecol Oncol; 1995 Jun; 57(3):388-94. PubMed ID: 7774843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumors.
    Allavena P; Zanaboni F; Rossini S; Merendino A; Bonazzi C; Vassena L; Mangioni C; Mantovani A
    J Natl Cancer Inst; 1986 Oct; 77(4):863-8. PubMed ID: 3489856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
    Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
    Bamias A; Tsiatas ML; Kafantari E; Liakou C; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Tsitsilonis O; Bamia C; Papatheodoridis G; Politi E; Archimandritis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2007 Jul; 106(1):75-81. PubMed ID: 17433425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic features of tumor-infiltrating lymphocytes and peripheral blood lymphocytes in ovarian cancer patients.
    Schöndorf T; Engel H; Kurbacher CM; Brenne U; Kolhagen H; Göhring UJ; Scharl A; Mallmann P
    J Soc Gynecol Investig; 1998; 5(2):102-7. PubMed ID: 9509389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Induction of T cell responses against autologous ovarian cancer by anti-idiotype minibody-pulsed dendritic cells].
    Yang WL; Cui H; Feng J; Chang XH; Fu TY; Ye X; Zhang H; Li XP; Wen HW; Feng LM; Tong CR
    Ai Zheng; 2004 Dec; 23(12):1639-45. PubMed ID: 15601552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
    Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
    Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocytes isolated from the peritoneal fluid of women with advanced ovarian carcinoma differ significantly from autologous peripheral blood lymphocytes.
    Melioli G; Ferrari I; Casartelli G; Ragni N
    Gynecol Oncol; 1993 Mar; 48(3):301-7. PubMed ID: 8462898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of bovine ocular squamous cell carcinoma: isolation, culture and characterization of lymphocytes present in the tumor.
    Rutten VP; De Jong WA; Klein WR; Den Otter W; Steerenberg PA; Ruitenberg EJ
    Anticancer Res; 1991; 11(3):1259-64. PubMed ID: 1888157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice.
    Voutsas IF; Pistamaltzian N; Tsiatas ML; Skopeliti M; Katsila T; Mavrothalassiti I; Spyrou S; Dimopoulos MA; Tsitsilonis OE; Bamias A
    Eur J Cancer; 2013 May; 49(7):1706-14. PubMed ID: 23276721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.